Bausch + Lomb Corporation (BLCO)

CA — Healthcare Sector

Peers: COO ICUI HOLX BDX TFX WST ALC RMD AKYA ATRC ATRI HAE ANGO ATR

Automate Your Wheel Strategy on BLCO

With Tiblio's Option Bot, you can configure your own wheel strategy including BLCO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol BLCO
Rev/Share 13.6763
Book/Share 18.2341
PB 0.6406
Debt/Equity 0.7592
CurrentRatio 1.5608
ROIC 0.0081

MktCap 4081731192.0
FreeCF/Share -0.4745
PFCF -24.3813
PE -8.316
Debt/Assets 0.3596
DivYield 0
ROE -0.0756

Rating C+
Score 2
Recommendation Sell
P/E Score 1
DCF Score 4
P/B Score 4
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Reiterated	BLCO	H.C. Wainwright	--	Buy	$20	$15	May 2, 2025
Downgrade	BLCO	Wells Fargo	Overweight	Equal Weight	$24	$15	March 28, 2025
Downgrade	BLCO	Citigroup	Buy	Neutral	$24	$22	Dec. 11, 2024
Upgrade	BLCO	Evercore ISI	In-line	Outperform	$19	$25	Oct. 15, 2024

News

Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

BLCO
Published: March 26, 2025 by: Business Wire
Sentiment: Neutral

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of th.

image for news Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

Bausch + Lomb (BLCO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

BLCO
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

image for news Bausch + Lomb (BLCO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

1
2 (current)

About Bausch + Lomb Corporation (BLCO)

IPO Date 2022-05-06
Website https://www.bausch.com
Industry Medical - Instruments & Supplies
CEO Mr. Brenton L. Saunders J.D.
Employees 13500

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.